Online citations, reference lists, and bibliographies.
← Back to Search

Application Of RPMI 2650 As A Cell Model To Evaluate Solid Formulations For Intranasal Delivery Of Drugs.

V. S. Gonçalves, A. A. Matias, J. Poejo, A. T. Serra, C. Duarte
Published 2016 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
During the development of intranasal drug delivery systems for local/systemic effect or brain targeting, it is necessary to assess its cytotoxicity and drug transport through nasal epithelium. In order to avoid animal experiments or the use of excised tissues, in vitro cell models, such as RPMI 2650 cells, are being preferred during recent years. Nevertheless, the deposition of solid formulations into nasal cell layers with further transepithelial transport rate of drugs has been poorly studied or reported. Thus, the purpose of this work is to further investigate RPMI 2650 cell line as an effective alternative to animal tissues for solid drug-loaded formulations cytotoxicity and drug permeation studies in order to become an option as a tool for drug discovery. Furthermore, we wanted to determine the extent to which the administration of drugs in particulate forms would differ in relation to the permeability of the same compounds applied as solutions. RPMI 2650 cells were cultured in submersed or at air-liquid interface conditions and characterized regarding transepithelial electrical resistance (TEER) and production of mucus. Pure ketoprofen (used as model compound) and five formulations loaded with same drug, namely solid lipid particles (Gelucire 43/01™), structured lipid particles (Gelucire 43/01™:Glyceryl monooleate) and aerogel microparticles (Alginate, Alginate:Pectin, Alginate:Carrageenan), were evaluated with RPMI 2650 model in terms of cytotoxicity and permeability of drug (applied as solution, dispersion or powder+buffer). RPMI 2650 cells were capable to grow in monolayer and multilayer, showing the same permeability as excised human nasal mucosa for sodium fluorescein (paracellular marker), with analogous TEER values and production of mucus, as referred by other authors. None of the powders showed cytotoxicity when applied to RPMI 2650 cells. Regarding permeation of drug through cell layers, not only the form of application of powders but also their physical and chemical properties affected the final permeation of active pharmaceutical ingredient. Aerogel microparticles administered directly to the cell layer (powder+buffer) exhibited the highest permeation-enhancing effect compared to the pure drug, which can be attributed to the mucoadhesive properties of the materials composing the carriers, proving to be an attractive formulation for nasal drug delivery. According to these results, RPMI 2650 showed to be a promising alternative to ex vivo or in vivo nasal models for cytotoxicity and evaluation of drug permeability of nasal drug-loaded formulations.
This paper references
Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability
Levente Kürti (2012)
Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model
S. Eskandari (2011)
Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells.
Anne M Dolberg (2016)
The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa.
C. I. Grainger (2009)
Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells
Tamás Horváth (2016)
In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration.
Levente Kürti (2013)
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
Viscometric study of pectin–mucin interaction and its mucoadhesive bond strength
Nartaya Thirawong (2008)
Passive Absorption of Drugs in Caco-2 Cells
P. Artursson (1991)
Global Food Demand Scenarios for the 21st Century
B. Bodirsky (2015)
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro
C. Meindl (2015)
Nanoparticles for direct nose-to-brain delivery of drugs.
Alpesh Mistry (2009)
Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment
S. Singh (2016)
The permeability of large
L. L. Greenwell (2009)
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.
C. Dufès (2003)
Cultivation of RPMI 2650 cells as an in‐vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions
S. Reichl (2012)
Influence of Dosage Form, Formulation, and Delivery Device on Olfactory Deposition and Clearance: Enhancement of Nose-to-CNS Uptake
Dipy M. Vasa (2015)
Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies.
E. Gavini (2006)
Filtration methodologies for the clarification and concentration of human mesenchymal stem cells
B. Cunha (2015)
Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion
Ayumu Asai (2015)
Adsorption of Drugs on Silica Aerogels
I. Smirnova (2003)
Polysaccharide-based aerogel microspheres for oral drug delivery.
C. García-González (2015)
Carrageenan and its applications in drug delivery.
L. Li (2014)
Alginate-based hybrid aerogel microparticles for mucosal drug delivery.
V. S. Gonçalves (2016)
Preparation of macroporous alginate-based aerogels for biomedical applications
Marta Martins (2015)
The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal Model
M. E. Kreft (2014)
A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Stephanie Hein (2011)
Evaluation of the appropriate time range for estimating the apparent permeability coefficient (P(app)) in a transcellular transport study.
Kazuhisa Ozeki (2015)
Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids.
S. Grassin-Delyle (2012)
In‐vitro nasal drug delivery studies: comparison of derivatised, fibrillar and polymerised collagen matrix‐based human nasal primary culture systems for nasal drug delivery studies
R. Agu (2001)
Nanoparticle transport across in vitro olfactory cell monolayers.
O. Gartziandia (2016)
Cell culture sheets to study nasal peptide metabolism
Hagen Georg Peter (1996)
Exploring continuous and integrated strategies for the up- and downstream processing of human mesenchymal stem cells.
B. Cunha (2015)
The effect of sucrose esters on a culture model of the nasal barrier.
Levente Kürti (2012)
Alginate in Drug Delivery Systems
H. Tønnesen (2002)
Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies.
Shuhua Bai (2008)
The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor‐β gene expression and protein release
R. Salib (2005)
Supercritical fluid precipitation of ketoprofen in novel structured lipid carriers for enhanced mucosal delivery--a comparison with solid lipid particles.
V. S. Gonçalves (2015)
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
P. Djupesland (2012)
Drug Permeation
A. Asai (2016)
Time- and passage
P. M. Young (2010)
The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.
P. Djupesland (2014)
Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting
C. Pardeshi (2013)
Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model
M. Haghi (2010)
Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine.
S. Lungare (2016)
Optimization of Caco-2 and HT29 co-culture in vitro cell models for permeability studies
F. Pan (2015)
Cadmium-induced up-regulation of aldo-keto reductase 1C3 expression in human nasal septum carcinoma RPMI-2650 cells: Involvement of reactive oxygen species and phosphatidylinositol 3-kinase/Akt.
Yoon-Jin Lee (2011)
Serially Passaged Human Nasal Epithelial Cell Monolayer for in Vitro Drug Transport Studies
Jin-Wook Yoo (2004)
Sterilization on dextran-coated iron oxide nanoparticles: Effects of autoclaving, filtration, UV irradiation, and ethanol treatment
L. Li (2013)
Cell-based in vitro models for nasal permeability studies
Flávia Sousa (2016)
In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride.
G. Fotakis (2006)
RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies.
Annette Wengst (2010)

This paper is referenced by
Development of Binary Composite Solid Microparticles for Improved Intranasal Absorption of Low Permeation Drug Molecules
Dipy M. Vasa (2017)
Ionel Fizeșan (2018)
Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds
Hanieh Gholizadeh (2019)
How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods
Laurent Salade (2019)
CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations
S. Yadav (2019)
Innovations in Antimicrobial Engineered Nanomaterials
M. P. Bernardo (2019)
Altered polarization of PAR-2 signaling during airway epithelial remodeling
R. Carey (2020)
Recent advances in carrier mediated nose‐to‐brain delivery of pharmaceutics
V. Bourganis (2018)
Polarization of protease-activated receptor 2 (PAR-2) signaling is altered during airway epithelial remodeling and deciliation
R. Carey (2020)
Evaluation of intranasal delivery route of drug administration for brain targeting
F. Erdő (2018)
Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
Simone Ladel (2019)
The construction of in vitro nasal cavity-mimic M-cell model, design of M cell-targeting nanoparticles and evaluation of mucosal vaccination by nasal administration
Xiaotong Yang (2020)
Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?
C. Mercier (2017)
Semantic Scholar Logo Some data provided by SemanticScholar